Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • fertility

    - PMLiVE

    Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug

    Cladribine capsules could become the first ever oral treatment for gMG

    - PMLiVE

    Lilly to spend $6.5bn on second of four US manufacturing facilities

    The new facility in Texas is expected to create 4,615 manufacturing and construction jobs

    - PMLiVE

    Lilly to invest $5bn in US manufacturing facility

    The company will create 2,450 high-wage manufacturing and construction jobs

    - PMLiVE

    Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries

    Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...

    Uniphar

    Dave Miller on Biotechs image

    Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies

    HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.

    Genesis Research Group

    - PMLiVE

    Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition

    SpringWorks’ Gomekli was approved by the FDA earlier this year to treat patients with NF1

    - PMLiVE

    Medscape Education Global to Join Biotechs at Swiss Biotech Day

    The Medscape Education Global team is excited to announce its participation in Swiss Biotech Day, taking place in Basel from May 5-6. This marks our inaugural attendance at this event,...

    Medscape Education

    - PMLiVE

    Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

    The neurological disorder affects more than 150,000 people in the UK

    - PMLiVE

    Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type

    The companies entered into a licensing agreement for the candidate in December last year

    - PMLiVE

    Merck KGaA signs definitive agreement to acquire Mirus Bio in deal worth $600m

    The deal aims to advance Merck’s viral vector manufacturing of cell and gene therapies

    - PMLiVE

    Merck KGaA and Caris enter oncology partnership worth over $1.4bn

    The alliance is aimed at accelerating the development of ADCs for cancer patients

    - PMLiVE

    Merck KGaA and C4 Therapeutics enter protein degrader partnership worth $756m

    The collaboration will utilise C4T’s TORPEDO platform to target and degrade disease-associated proteins

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links